Overslaan en naar de inhoud gaan

 Wetenschapelijke artikelen

Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer.

Auteurs : Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothé F, Sotiriou C
Jaar : 2019
Journal : Breast Cancer Res
Volume : 21
Pagina's : 25

CTCs as a prognostic and predictive biomarker for stage II/III Colon Cancer: a companion study to the PePiTA trial.

Auteurs : Rothé F, Maetens M, Rouas G, Paesmans M, Van den Eynde M, Van Laethem JL, Vergauwe P, Deboever G, Bareche Y, Vandeputte C, Ignatiadis M, Hendlisz A
Jaar : 2019
Journal : BMC Cancer
Volume : 19
Pagina's : 304

Immune Infiltration in Invasive Lobular Breast Cancer.

Auteurs : Desmedt C, Salgado R, Fornili M, Pruneri G, Van den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, Brown D, Bareche Y, Rouas G, Galant C, Bertucci F, Loi S, Viale G, Di Leo A, Green AR, Ellis IO, Rakha EA, Larsimont D, Biganzoli E, Sotiriou C
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(7)
Pagina's : 768-776

Genomic hotspots but few recurrent fusion genes in breast cancer.

Auteurs : Fimereli D, Fumagalli D, Brown D, Gacquer D, Rothé F, Salgado R, Larsimont D, Sotiriou C, Detours V
Jaar : 2018
Journal : Genes Chromosomes Cancer
Volume : 57(7)
Pagina's : 331-338

Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis.

Auteurs : Bareche Y, Venet D, Ignatiadis M, Aftimos P, Piccart-Gebhart M, Rothé F, Sotiriou C
Jaar : 2018
Journal : Ann Oncol
Volume : 29(4)
Pagina's : 895-902

Trastuzumab versus observation for HER2 non amplified early breast cancer with Circulating Tumor Cells (EORTC 90091-10093, BIG 1-12, Treat CTC): A randomized phase 2 trial.

Auteurs : Ignatiadis M, Litière S, Rothé F, Riethdorf S, Proudhon C, Fehm T, Aalders K, Forstbauer H, Fasching P, Brain E, Vuylsteke P, Guardiola E, Lorenz R, Pantel K, Tryfonidis K, Janni W, Piccart-Gebhart M, Sotiriou C, Rack B, Pierga JY
Jaar : 2018
Journal : Ann Oncol
Volume : 29(8)
Pagina's : 1777-1783

Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis.

Auteurs : Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, dHollander K, Pantel K
Jaar : 2018
Journal : J Natl Cancer Inst
Volume : 110(6)
Pagina's : 560-567

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.

Auteurs : Jose V, Fumagalli D, Rothé F, Majjaj S, Loi S, Michiels S, Sotiriou C
Jaar : 2018
Journal : PLoS One
Volume : 13
Pagina's : e0203346

Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations.

Auteurs : Nguyen B, Venet D, Azim HA Jr, Brown D, Desmedt C, Lambertini M, Majjaj S, Pruneri G, Peccatori F, Piccart-Gebhart M, Rothé F, Sotiriou C
Jaar : 2018
Journal : NPJ Breast Cancer
Volume : 4
Pagina's : 23

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.

Auteurs : Fumagalli D, Venet D, Ignatiadis M, Azim HA Jr, Maetens M, Rothé F, Salgado R, Bradbury I, Pusztai L, Harbeck N, Gomez H, Chang TW, Coccia-Portugal MA, Di Cosimo S, de Azambuja E, de la Peña L, Nuciforo P, Brase JC, Huober J, Baselga J, Piccart-Gebhart M, Loi S, Sotiriou C
Jaar : 2017
Journal : JAMA Oncol
Volume : 3
Pagina's : 227-234

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Jaar : 2017
Journal : Nat Commun
Volume : 8
Pagina's : 15759

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Auteurs : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Jaar : 2017
Journal : Mod Pathol
Volume : 30(9)
Pagina's : 1204-1212

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Jaar : 2017
Journal : Nat Commun
Volume : 8
Pagina's : 14944

The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group.

Auteurs : Maetens M, Brown D, Irrthum A, Aftimos P, Viale G, Loibl S, Laes JF, Campbell PJ, Thompson A, Cortes J, Seiler S, Vinnicombe S, Oliveira M, Rothé F, Bareche Y, Fumagalli D, Zardavas D, Desmedt C, Piccart-Gebhart M, Loi S, Sotiriou C
Jaar : 2017
Journal : NPJ Breast Cancer
Volume : 3
Pagina's : 23

CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib.

Auteurs : Raspé E, Coulonval K, Pita JM, Paternot S, Rothé F, Twyffels L, Brohée S, Craciun L, Larsimont D, Kruys V, Sandras F, Salmon I, Van Laere S, Piccart-Gebhart M, Ignatiadis M, Sotiriou C, Roger PP
Jaar : 2017
Journal : EMBO Mol Med
Volume : 9
Pagina's : 1052-1066

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

Auteurs : Fumagalli D, Wilson TR, Salgado R, Lu X, Yu J, OBrien C, Walter K, Huw LY, Criscitiello C, Laios I, Jose V, Brown DN, Rothé F, Maetens M, Zardavas D, Savas P, Larsimont D, Piccart-Gebhart M, Michiels S, Lackner MR, Sotiriou C, Loi S
Jaar : 2016
Journal : Ann Oncol
Volume : 27
Pagina's : 1860-6

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Auteurs : Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C
Jaar : 2016
Journal : J Clin Oncol
Volume : 34(16)
Pagina's : 1872-81

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial.

Auteurs : Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H, Dittrich C, Messina C, Beauvois M, Trapp E, Goulioti T, Tryfonidis K, Pantel K, Repollet M, Janni W, Piccart-Gebhart M, Sotiriou C, Litiere S, Pierga JY
Jaar : 2016
Journal : Eur J Cancer
Volume : 63
Pagina's : 97-104

MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.

Auteurs : Denis H, Van Grembergen O, Delatte B, Dedeurwaerder S, Putmans P, Calonne E, Rothé F, Sotiriou C, Fuks F, Deplus R
Jaar : 2016
Journal : Mol Biosyst
Volume : 12(2)
Pagina's : 404-13

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.

Auteurs : Ignatiadis M, Azim HA Jr, Desmedt C, Veys I, Larsimont D, Salgado R, Lyng MB, Viale G, Leyland-Jones B, Giobbie-Hurder A, Kammler R, Dell orto P, Rothé F, Laïos I, Ditzel HJ, Regan MM, Piccart-Gebhart M, Michiels S, Sotiriou C
Jaar : 2016
Journal : JAMA Oncol
Volume : 2(2)
Pagina's : 217-24